Posts

Video how the LRC-TriCEPS™ technology works

Video – how the LRC-TriCEPS™ technology works

Dualsystems Biotech AG Press Release

How the LRC-TriCEPS™ technology works (Video)

Zürich Switzerland – June 23, 2014 – Dualsystems Biotech AG offers the most advanced technology for identifying receptor(s) for orphan ligands. The ligand-receptor capture technology (LRC-TriCEPS™) is an innovative and conceptually new approach for the unbiased discovery of cell surface interactions of ligands ranging from peptides, proteins, antibodies to viruses. Dualsystems offers the LRC-TriCEPS™ technology in our service line CaptiRec. We offer a variety of formats which will fit your needs: From CaptiRec Kits for your own in-house experiments to an all-inclusive CaptiRec Service.

Dualsystems Biotech AG is looking forward to support your project with the newest invention in receptor/target discovery.

Please watch the video where we explain how the LRC-TriCEPS™ technology works: LRC-TriCEPS™-Video

Video-Dualsystems-LRC-Triceps

How the LRC-TriCEPS™ technology works

Video how the LRC-TriCEPS™ technology works


LRC-TriCEPS™  is a novel approach which enables the identification of cell surface receptors and off-targets on the living cells for a wide range of orphan ligands, such as:

  • Peptides
  • Protein
  • Antibodies
  • Engineered affinity binders
  • Viruses

Watch the video to see how the LRC-TriCEPS™ technology works


Testimonials:

  • University of Manitoba
  • The Rockefeller University
  • Medizinische Hochschule Hannover
  • Igenica Biotherapeutics (USA)
  • University of California San Francisco (UCSF)
  • CEDOC – Centro de Estudos de Doenças Crónicas
  • Washington University School of Medicine

More details to all testimonials

Video interview about CaptiRec Services (LRC)

Video interview of CaptiRec Services, ligand-receptor capture technology (LRC) with Dr. Paul Helbling, the new management of Dualsystems Biotech AG.

 

Licensing Agreement with ETH Zurich on LRC technoloy

Dualsystems Biotech closes Licensing Agreement with ETH Zurich on Ligand Receptor Capture (LRC) technology

Dualsystems Biotech has licensed an innovative technology to discover cell-surface receptors for a vast range of ligands of interest. LRC is centered around an innovative trifunctional chemoproteomic reagent named TriCEPS™, which enables the unbiased identification of cell surface receptors for many types of ligands, such as peptides, proteins, antibodies, engineered affinity binders or viruses. Receptor capture takes place under near-physiological conditions on native tissues and cells, without the need for genetic manipulations. Read more

Pages

Video-Dualsystems-LRC-Triceps

How the LRC-TriCEPS™ technology works

Video how the LRC-TriCEPS™ technology works


LRC-TriCEPS™  is a novel approach which enables the identification of cell surface receptors and off-targets on the living cells for a wide range of orphan ligands, such as:

  • Peptides
  • Protein
  • Antibodies
  • Engineered affinity binders
  • Viruses

Watch the video to see how the LRC-TriCEPS™ technology works


Testimonials:

  • University of Manitoba
  • The Rockefeller University
  • Medizinische Hochschule Hannover
  • Igenica Biotherapeutics (USA)
  • University of California San Francisco (UCSF)
  • CEDOC – Centro de Estudos de Doenças Crónicas
  • Washington University School of Medicine

More details to all testimonials